Wesley H Self1, Matthew W Semler1, Jonathan P Wanderer1, Li Wang1, Daniel W Byrne1, Sean P Collins1, Corey M Slovis1, Christopher J Lindsell1, Jesse M Ehrenfeld1, Edward D Siew1, Andrew D Shaw1, Gordon R Bernard1, Todd W Rice1. 1. From the Departments of Emergency Medicine (W.H.S., S.P.C., C.M.S.), Anesthesiology (J.P.W., J.M.E., A.D.S.), Biomedical Informatics (J.P.W., J.M.E.), and Biostatistics (L.W., D.W.B., C.J.L.), the Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine (M.W.S., G.R.B., T.W.R.), and the Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt Center for Kidney Disease and Integrated Program for Acute Kidney Injury Research (E.D.S.), Vanderbilt University Medical Center, Nashville.
Abstract
BACKGROUND: Comparative clinical effects of balanced crystalloids and saline are uncertain, particularly in noncritically ill patients cared for outside an intensive care unit (ICU). METHODS: We conducted a single-center, pragmatic, multiple-crossover trial comparing balanced crystalloids (lactated Ringer's solution or Plasma-Lyte A) with saline among adults who were treated with intravenous crystalloids in the emergency department and were subsequently hospitalized outside an ICU. The type of crystalloid that was administered in the emergency department was assigned to each patient on the basis of calendar month, with the entire emergency department crossing over between balanced crystalloids and saline monthly during the 16-month trial. The primary outcome was hospital-free days (days alive after discharge before day 28). Secondary outcomes included major adverse kidney events within 30 days - a composite of death from any cause, new renal-replacement therapy, or persistent renal dysfunction (defined as an elevation of the creatinine level to ≥200% of baseline) - all censored at hospital discharge or 30 days, whichever occurred first. RESULTS: A total of 13,347 patients were enrolled, with a median crystalloid volume administered in the emergency department of 1079 ml and 88.3% of the patients exclusively receiving the assigned crystalloid. The number of hospital-free days did not differ between the balanced-crystalloids and saline groups (median, 25 days in each group; adjusted odds ratio with balanced crystalloids, 0.98; 95% confidence interval [CI], 0.92 to 1.04; P=0.41). Balanced crystalloids resulted in a lower incidence of major adverse kidney events within 30 days than saline (4.7% vs. 5.6%; adjusted odds ratio, 0.82; 95% CI, 0.70 to 0.95; P=0.01). CONCLUSIONS: Among noncritically ill adults treated with intravenous fluids in the emergency department, there was no difference in hospital-free days between treatment with balanced crystalloids and treatment with saline. (Funded by the Vanderbilt Institute for Clinical and Translational Research and others; SALT-ED ClinicalTrials.gov number, NCT02614040 .).
RCT Entities:
BACKGROUND: Comparative clinical effects of balanced crystalloids and saline are uncertain, particularly in noncritically ill patients cared for outside an intensive care unit (ICU). METHODS: We conducted a single-center, pragmatic, multiple-crossover trial comparing balanced crystalloids (lactated Ringer's solution or Plasma-Lyte A) with saline among adults who were treated with intravenous crystalloids in the emergency department and were subsequently hospitalized outside an ICU. The type of crystalloid that was administered in the emergency department was assigned to each patient on the basis of calendar month, with the entire emergency department crossing over between balanced crystalloids and saline monthly during the 16-month trial. The primary outcome was hospital-free days (days alive after discharge before day 28). Secondary outcomes included major adverse kidney events within 30 days - a composite of death from any cause, new renal-replacement therapy, or persistent renal dysfunction (defined as an elevation of the creatinine level to ≥200% of baseline) - all censored at hospital discharge or 30 days, whichever occurred first. RESULTS: A total of 13,347 patients were enrolled, with a median crystalloid volume administered in the emergency department of 1079 ml and 88.3% of the patients exclusively receiving the assigned crystalloid. The number of hospital-free days did not differ between the balanced-crystalloids and saline groups (median, 25 days in each group; adjusted odds ratio with balanced crystalloids, 0.98; 95% confidence interval [CI], 0.92 to 1.04; P=0.41). Balanced crystalloids resulted in a lower incidence of major adverse kidney events within 30 days than saline (4.7% vs. 5.6%; adjusted odds ratio, 0.82; 95% CI, 0.70 to 0.95; P=0.01). CONCLUSIONS: Among noncritically ill adults treated with intravenous fluids in the emergency department, there was no difference in hospital-free days between treatment with balanced crystalloids and treatment with saline. (Funded by the Vanderbilt Institute for Clinical and Translational Research and others; SALT-ED ClinicalTrials.gov number, NCT02614040 .).
Authors: Bram Rochwerg; Waleed Alhazzani; Anees Sindi; Diane Heels-Ansdell; Lehana Thabane; Alison Fox-Robichaud; Lawrence Mbuagbaw; Wojciech Szczeklik; Fayez Alshamsi; Sultan Altayyar; Wang-Chun Ip; Guowei Li; Michael Wang; Anna Wludarczyk; Qi Zhou; Gordon H Guyatt; Deborah J Cook; Roman Jaeschke; Djillali Annane Journal: Ann Intern Med Date: 2014-09-02 Impact factor: 25.391
Authors: Feihu Zhou; Zhi-Yong Peng; Jeffery V Bishop; Matthew E Cove; Kai Singbartl; John A Kellum Journal: Crit Care Med Date: 2014-04 Impact factor: 7.598
Authors: Nor'azim Mohd Yunos; Rinaldo Bellomo; Colin Hegarty; David Story; Lisa Ho; Michael Bailey Journal: JAMA Date: 2012-10-17 Impact factor: 56.272
Authors: Paul Young; Michael Bailey; Richard Beasley; Seton Henderson; Diane Mackle; Colin McArthur; Shay McGuinness; Jan Mehrtens; John Myburgh; Alex Psirides; Sumeet Reddy; Rinaldo Bellomo Journal: JAMA Date: 2015-10-27 Impact factor: 56.272
Authors: Cameron P Upchurch; Carlos G Grijalva; Stephan Russ; Sean P Collins; Matthew W Semler; Todd W Rice; Dandan Liu; Jesse M Ehrenfeld; Kevin High; Tyler W Barrett; Candace D McNaughton; Wesley H Self Journal: Ann Emerg Med Date: 2017-01 Impact factor: 5.721
Authors: Fernando G Zampieri; Luciano C P Azevedo; Thiago D Corrêa; Maicon Falavigna; Flavia R Machado; Murillo S C de Assunção; Suzana M A Lobo; Letícia K Dourado; Otavio Berwanger; John A Kellum; Nilton Brandão; Alexandre B Cavalcanti Journal: Crit Care Resusc Date: 2017-06 Impact factor: 2.159
Authors: Andrew D Shaw; Karthik Raghunathan; Fred W Peyerl; Sibyl H Munson; Scott M Paluszkiewicz; Carol R Schermer Journal: Intensive Care Med Date: 2014-10-08 Impact factor: 17.440
Authors: Johan Mårtensson; Shailesh Bihari; Jonathan Bannard-Smith; Neil J Glassford; Patryck Lloyd-Donald; Luca Cioccari; Nora Luethi; Aiko Tanaka; Marco Crisman; Nicolas Rey de Castro; Marcus Ottochian; Agnes Huang; Maria Cronhjort; Andrew D Bersten; Shivesh Prakash; Michael Bailey; Glenn M Eastwood; Rinaldo Bellomo Journal: Intensive Care Med Date: 2018-10-21 Impact factor: 17.440
Authors: Maurizio Cecconi; Glenn Hernandez; Martin Dunser; Massimo Antonelli; Tim Baker; Jan Bakker; Jacques Duranteau; Sharon Einav; A B Johan Groeneveld; Tim Harris; Sameer Jog; Flavia R Machado; Mervyn Mer; M Ignacio Monge García; Sheila Nainan Myatra; Anders Perner; Jean-Louis Teboul; Jean-Louis Vincent; Daniel De Backer Journal: Intensive Care Med Date: 2018-11-19 Impact factor: 17.440
Authors: Andrew Friederich; Natalie Martin; Morgan B Swanson; Brett A Faine; Nicholas M Mohr Journal: Ann Emerg Med Date: 2018-08-23 Impact factor: 5.721